| Datum | Zeit | Quelle | Überschrift | Symbol | Firma |
| 03/03/2025 | 06h15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 25/02/2025 | 22h01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 20/02/2025 | 22h01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 18/02/2025 | 13h30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 14/02/2025 | 23h01 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 04/02/2025 | 22h45 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 04/02/2025 | 22h05 | Edgar (US Regulatory) | Form 5 - Annual statement of changes in beneficial ownership of securities | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 28/01/2025 | 13h30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 07/01/2025 | 13h30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 23/12/2024 | 13h00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 20/12/2024 | 23h00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 11/12/2024 | 22h01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 02/12/2024 | 22h01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 25/11/2024 | 23h06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 21/11/2024 | 22h15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 20/11/2024 | 22h15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 12/11/2024 | 22h05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 27/09/2024 | 22h15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 12/08/2024 | 14h30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 02/07/2024 | 14h30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 17/06/2024 | 22h10 | GlobeNewswire Inc. | Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 30/05/2024 | 14h30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1 | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 24/05/2024 | 15h30 | GlobeNewswire Inc. | New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 16/05/2024 | 15h30 | GlobeNewswire Inc. | Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 13/05/2024 | 22h31 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 16/04/2024 | 14h30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C. | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 02/04/2024 | 14h30 | GlobeNewswire Inc. | Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024 | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 29/03/2024 | 21h44 | GlobeNewswire Inc. | UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 26/03/2024 | 13h30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 22/03/2024 | 13h30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
